Markets

Novartis: In the Pipeline

This major pharmaceutical company may be the best positioned among its peers.

Novartis AG, the giant, Swiss-based drugmaker, sells at about $57 a share -- just $5 more than it sold for in 1999. But the stock's tepid appreciation seems likely to accelerate over the next several years.

Novartis on Monday reported that first-quarter earnings rose 32% from the same period a year ago, to 83 cents per share. Part of the increase was attributed to lower marketing costs, but most was because of a 13% increase in sales, to $8.3 billion. The stock, however, barely budged because analysts -- while surprised by the robust earnings number -- had, on average, expected revenues of $8.5 billion.

But Novartis may well be the best positioned of the major pharmaceutical companies. It has four blockbuster drugs -- drugs with annual sales over $1 billion. They are leukemia drug Gleevec; Lotrel and Diovan for hypertension; and Zometa, another cancer drug. Sales of all four are still growing at double-digit annual rates.

The pipeline? "That's where it gets really exciting," says Trevor Polischuk, an analyst with Orbimed Advisors, which manages Eaton Vance Worldwide Health Sciences fund. Novartis is the largest holding in the fund at more than 7% of assets. Novartis just filed with the Food and Drug Administration for approval of two new drugs, one for hypertension and one for diabetes. "They'll be first-in-class drugs," says Polischuk. "They're not 'me-too' drugs." In addition, he says, Novartis boasts "a whole host" of other promising drugs in its pipeline.

What's more, Novartis faces few expiring patents in the near future, a problem that bedevils many other big pharmaceutical companies. Only one of its key drugs will lose patent protection by the end of the decade. Novartis must contend with some of the same pressures that other drug companies face, however -- most important, pressure by governments around the world to stem rapidly rising drug costs.

Chief executive Dan Vasella has done a fine job fostering the right atmosphere to keep research scientists developing new drugs. He worries some on Wall Street, though, because he's acquisitive. But Novartis's most recent purchase, biotech company Chiron, looks promising. "Novartis has deep pockets, tons of cash flow and a great balance sheet," Polischuk says. Indeed, debt is just 4% of capital, and the firm has $11 billion in cash and securities.

The stock (symbol NVS) sells at 17 times Polischuk's 2006 earnings estimate of $3.32 per share. That's about the same price-earnings ratio as most of Novartis's rivals. But Polischuk figures that Novartis's earnings will grow 17% per year through 2009 -- much more than its competitors. "On a price-earnings-to-growth basis, Novartis is the cheapest of all the big pharma companies" he says.

--Steven Goldberg

Most Popular

What Are the Income Tax Brackets for 2022 vs. 2021?
tax brackets

What Are the Income Tax Brackets for 2022 vs. 2021?

Depending on your taxable income, you can end up in one of seven different federal income tax brackets – each with its own marginal tax rate.
September 20, 2022
Your Guide to Roth Conversions
Special Report
Tax Breaks

Your Guide to Roth Conversions

A Kiplinger Special Report
February 25, 2021
I’ve Inherited a Lot of Money. Now What?
estate planning

I’ve Inherited a Lot of Money. Now What?

First, put all major decisions on hold. A financial planner can help you come up with a plan that addresses your goals, dreams and needs.
September 25, 2022

Recommended

8 Facts You Must Know About Bear Markets
investing

8 Facts You Must Know About Bear Markets

All three major indexes are now in a bear market. And while bear markets can be terrifying, they're normal, inevitable and – most importantly – don't…
September 27, 2022
This New Sustainable ETF’s Pitch? Give Back Profits.
investing

This New Sustainable ETF’s Pitch? Give Back Profits.

Newday’s ETF partners with UNICEF and other groups.
September 26, 2022
Stock Market Today (9/26/22): Dow Officially Enters a Bear Market After Monday's Slide
Stock Market Today

Stock Market Today (9/26/22): Dow Officially Enters a Bear Market After Monday's Slide

Casino stocks were a pocket of strength after Macau said it will ease COVID-related travel restrictions in November.
September 26, 2022
Stock Market Today (9/23/22): Dow Plummets 486 Points, Nears Bear Market
Stock Market Today

Stock Market Today (9/23/22): Dow Plummets 486 Points, Nears Bear Market

The selling wasn't confined to the equities market, with crude oil, gold and Bitcoin all suffering steep losses.
September 23, 2022